Morgan, G.

patient lenalidomide myeloma len /dex therapy dexamethasone treatment blood study ef ficacy university transplant trial response mobilization hospital department transplantation leukemia panel consensus disease combination thalidomide cycle factor autologou celgene dimopoulo collection outcome marrow cell mobilization fi rst relapse event ficacy cell collection result cell transplantation plerixafor len /dex therapy high-dose group high-dose therapy survival myeloma patients effect bene fit g-csf cancer reduction cytogenetic abnormalities ash annu table impact neutropenia statement month novel regimen cytogenetic analysis neuropathy bortezomib center attal m function chemotherapy strategy signi ficantly hematology creatinine clearance baseline relapse prophylaxi mayo clinic institute progression board abnormality